News

The 455-patient randomized, double-masked, vehicle-controlled, dose-ranging study (ClinicalTrials.gov Identifier: NCT02254265) was conducted at 28 investigational sites in the U.S. In the study, both concentrations (0.05% and 0.09%) of

Epic Sciences president and CEO Murali Prahalad said: "Successful treatment of cancer depends on understanding the heterogeneity of the patient’s tumor burden and the driving genetic alterations behind

HEALOS will evaluate the efficacy, safety and tolerability of single dose intratympanic injections of AM-111 in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL; a.k.a. "sudden deafness").

The Orphan Drug Designation has been granted for the combination of two active ingredients of AB569: sodium nitrite and ethylenediaminetetraacetic acid. AB569 is to be administered to patients

Mylan offered $75 in cash and 2.3 ordinary shares for each Perrigo share. Perrigo has however called the Mylan proposal inadequate. Following the offer expiry, Mylan executive chairman

The Phase III trial assessed Imbruvica plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The results

The nexgen-PTS expands the company’s microbial solutions offering within its microbiology portfolio, which features microbial detection, bioburden testing and microbial identification. The Endosafe nexgen-PTS features touch screen display,

Xadago, which is being developed by Zambon and its partner Newron Pharmaceuticals, was approved as add-on therapy to levodopa (L-dopa) alone or in combination with other PD therapies

Tagrisso is indicated to treat patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). In two clinical trials of 411 subjects, 57%